Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Genetic Disorders

FDA Approves Jardiance for Type 2 Diabetes; FDA...

FDA Approves Jardiance for the Treatment of Type 2 Diabetes in Children 10 Years and Older Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance® (empaglifloz...

Jun 27, 2023

Gene Therapies for Dystrophic Epidermolysis Bullosa
Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...

Find More
Pharma News for Kyverna, Annovis, Astellas, FibroGen
FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...

Find More
pharma-news-for-bms-teva-biogen-atsena-kiromic
FDA Grants Priority Review to BMS’ Luspatercept; Teva and MedinCell’s Risperidone FDA Approval; Biogens’s QALSODY FDA Accelerated Approval; FDA IND Authorization to Kiromic’s Deltacel; Atsena’s ATSN-201 FDA IND Clearance

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking to expand the current indication of luspatercept-aamt (Reblozyl) to include treatment of anemia in patients with very ...

Find More

More Views & Analysis

Pharma News for XORTX, Roche, Lantheus, Janssen, Daiichi Sankyo, bluebird bio, and POINT Biopharma Global
Janssen’s AKEEGA Approval; FDA Approves Roche’s Polivy Combo for Frontline B-cell Lymphoma; Daiichi Sankyo’s Quizartinib for Adults With FLT3-ITD-Positive AML; bluebird bio BLA for lovo-cel for Patients with Sickle Cell Disease; Fast Track Designation for Lu-PNT2002 for mCRPC Treatment; FDA Orphan Drug Designation to XORTX’s Oxypurinol

Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) had granted marketing authorization for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form...

Find More

Polymerase Chain Reaction Market Outlook and Forecast
Polymerase Chain Reaction (PCR) Market: Evaluating the Major Market Dynamics and Key Trends Driving the Growth

Polymerase Chain Reaction, commonly called PCR, is one of the most well-known methods in molecular biology utilized for amplifying target sequences from a DNA template in an exponential manner. PCR has various applications, and the scope is vast in healthcare and other related domains. It was invented in 1983 by Am...

Find More

daybue-for-rett-syndrome-treatment
DAYBUE: First and Only Approved Drug for Rett Syndrome Treatment

Rett syndrome is a rare progressive neurodevelopmental disorder primarily affecting women. Males are only occasionally affected. Infants with Rett syndrome typically develop normally for the first 7 to 18 months of life. The Rett syndrome prevalence in the United States is estimated to be 1 in 10K girls by the age ...

Find More

Pharma news and updates for Roche, Acadia, Shorla Oncology, Calliditas, Mesoblast, Sanofi, Provention Bio
Sanofi to Acquire Provention Bio; USFDA Committee Votes in Favor Roche’s Polivy; FDA to Review Mesoblast’s GvHD Drug; FDA Approves Acadia’s Daybue ; FDA Approves Nelarabine Injection; Calliditas’s Nefecon Trial Reuslt in IgA Nephropathy

Sanofi to Acquire Provention Bio for USD 2.9 Billion Sanofi and Provention Bio, Inc., a publicly traded biopharmaceutical company based in the United States focused on intercepting and preventing immune-mediated diseases such as type 1 diabetes (T1D), have agreed to acquire Provention Bio, Inc. for $25.00 per sh...

Find More

Next-Generation Sequencing Market Trends, Development, Key Companies, Applications, and Future
Evaluating the Key Trends and Developments in the Global Next-Generation Sequencing Market

Next-Generation Sequencing (NGS) or commonly referred to as deep sequencing or massively parallel sequencing, is an important field of sequencing technology applied to determine the RNA or DNA sequence. It aims to provide detailed information about the genetic variation in organisms, diseases, or other biological p...

Find More

Pharma News and Updates for Actinium, Apellis, Chiesi, IVERIC, Travere, Takeda
Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older...

Find More

Progressive Supranuclear Palsy (PSP) is a rare progressive disorder resulting from damage that occur.....

Find More

Hemophilia, a genetic bleeding disorder characterized by a clotting factor protein deficiency. Intak.....

Find More

In the past few years, online buying has become the easiest way to purchase products and services. T.....

Find More

The coronavirus outbreak has affected thousands of people in at least 186 countries which has also a.....

Find More

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning .....

Find More

Molluscum contagiosum is an inflammation of the skin that is caused by the poxvirus Molluscum contag.....

Find More